Amgen Inc. $AMGN Shares Sold by D.A. Davidson & CO.

D.A. Davidson & CO. reduced its position in Amgen Inc. (NASDAQ:AMGN) by 2.7% during the 1st quarter, Holdings Channel.com reports. The firm owned 241,522 shares of the medical research company’s stock after selling 6,632 shares during the period. D.A. Davidson & CO.’s holdings in Amgen were worth $84,980,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in AMGN. Robeco Institutional Asset Management B.V. boosted its holdings in shares of Amgen by 10.0% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after acquiring an additional 43,884 shares during the last quarter. Curtis Advisory Group LLC acquired a new position in Amgen during the fourth quarter valued at $1,669,000. Adell Harriman & Carpenter Inc. lifted its position in Amgen by 7.9% during the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock valued at $7,204,000 after purchasing an additional 1,609 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new stake in Amgen in the fourth quarter valued at $22,441,000. Finally, Robinhood Asset Management LLC acquired a new stake in Amgen during the 4th quarter worth about $17,526,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.85% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. UBS Group lifted their price objective on Amgen from $400.00 to $420.00 and gave the company a “buy” rating in a research note on Monday. The Goldman Sachs Group set a $389.00 target price on Amgen in a report on Friday, June 5th. Daiwa Securities Group reduced their target price on Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research note on Wednesday, May 13th. Mizuho increased their target price on Amgen from $295.00 to $303.00 and gave the company a “neutral” rating in a research report on Tuesday, June 16th. Finally, Guggenheim lifted their price target on shares of Amgen from $340.00 to $343.00 and gave the company a “neutral” rating in a research note on Monday. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $356.62.

Amgen Price Performance

Shares of Amgen stock opened at $358.32 on Thursday. The business has a 50 day simple moving average of $346.15 and a two-hundred day simple moving average of $350.00. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $391.29. The stock has a market capitalization of $193.39 billion, a P/E ratio of 24.94, a PEG ratio of 3.59 and a beta of 0.41. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. During the same period in the previous year, the company posted $4.90 earnings per share. The business’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts predict that Amgen Inc. will post 22.31 EPS for the current fiscal year.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.